CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
486
Registration Number
NCT06543966

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

Phase 1
Not yet recruiting
Conditions
Hyperlipemia
Interventions
Drug: SYH2053
Drug: Placebo
First Posted Date
2024-01-29
Last Posted Date
2024-01-29
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
39
Registration Number
NCT06229548

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

First Posted Date
2023-12-27
Last Posted Date
2023-12-28
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
120
Registration Number
NCT06182592
Locations
🇨🇳

Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China

Bioequivalence of Amphotericin B Liposome for Injection

First Posted Date
2023-06-22
Last Posted Date
2023-09-28
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
32
Registration Number
NCT05913921
Locations
🇨🇳

Haikou people's Hospital, Haikou, Hainan, China

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Vyxeos
First Posted Date
2023-04-06
Last Posted Date
2023-09-21
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
36
Registration Number
NCT05801835
Locations
🇨🇳

Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China

A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

First Posted Date
2023-03-24
Last Posted Date
2023-03-24
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
398
Registration Number
NCT05783557

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

First Posted Date
2023-02-08
Last Posted Date
2023-02-08
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
500
Registration Number
NCT05717764

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

First Posted Date
2022-09-22
Last Posted Date
2024-08-07
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
46
Registration Number
NCT05551598
Locations
🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, Beijing, China

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

First Posted Date
2022-08-11
Last Posted Date
2022-12-15
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Registration Number
NCT05496894
Locations
🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, Beijing, China

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

First Posted Date
2021-09-22
Last Posted Date
2022-02-01
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
60
Registration Number
NCT05052970
Locations
🇨🇳

Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy